A continued focus on innovation in clinical trials is among the steps the US Food and Drug Administration could take to improve its response to the COVID-19 pandemic and future public health emergencies, a report commissioned by the agency concludes.
The recommendations are included in FDA’s COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) summary report, which notes that trial...







